Intec Pharma (NASDAQ:NTEC) Stock Price Up 26.7%

Intec Pharma Ltd (NASDAQ:NTEC) shares rose 26.7% on Friday . The company traded as high as $0.95 and last traded at $1.14, approximately 55,004 shares changed hands during trading. A decline of 98% from the average daily volume of 2,484,554 shares. The stock had previously closed at $0.90.

NTEC has been the subject of a number of recent analyst reports. LADENBURG THALM/SH SH reiterated a “hold” rating on shares of Intec Pharma in a research report on Monday, August 12th. ValuEngine upgraded shares of Intec Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Oppenheimer cut shares of Intec Pharma from an “outperform” rating to a “market perform” rating in a research report on Monday, July 22nd. Maxim Group cut shares of Intec Pharma from a “buy” rating to a “hold” rating in a research report on Monday, July 22nd. Finally, HC Wainwright cut shares of Intec Pharma from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 7th. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $12.17.

The firm has a market capitalization of $27.42 million, a price-to-earnings ratio of -0.82 and a beta of -0.01. The business’s 50-day simple moving average is $0.56 and its two-hundred day simple moving average is $4.41.

In other Intec Pharma news, CEO Jeffrey A. Meckler acquired 100,000 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The stock was purchased at an average price of $0.46 per share, for a total transaction of $46,000.00. Following the completion of the acquisition, the chief executive officer now owns 176,761 shares of the company’s stock, valued at approximately $81,310.06. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders purchased 145,000 shares of company stock valued at $71,350 in the last 90 days. Company insiders own 3.30% of the company’s stock.

Several hedge funds have recently made changes to their positions in the stock. River & Mercantile Asset Management LLP acquired a new position in shares of Intec Pharma in the second quarter valued at approximately $1,230,000. Morgan Stanley grew its holdings in shares of Intec Pharma by 38.4% in the second quarter. Morgan Stanley now owns 81,931 shares of the biotechnology company’s stock valued at $356,000 after purchasing an additional 22,715 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of Intec Pharma in the second quarter valued at approximately $593,000. Migdal Insurance & Financial Holdings Ltd. grew its holdings in shares of Intec Pharma by 25.9% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 729,193 shares of the biotechnology company’s stock valued at $3,165,000 after purchasing an additional 150,000 shares in the last quarter. Finally, JPMorgan Chase & Co. acquired a new position in shares of Intec Pharma in the second quarter valued at approximately $125,000. Hedge funds and other institutional investors own 35.51% of the company’s stock.

About Intec Pharma (NASDAQ:NTEC)

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.

Featured Story: Why do companies pay special dividends?

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.